Janux Therapeutics (JANX) Current Deferred Revenue (2020 - 2026)

Janux Therapeutics (JANX) has 6 years of Current Deferred Revenue data on file, last reported at $37.6 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $37.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $37.6 million (changed N/A YoY), and the FY2023 annual result was $1.7 million, down 68.46% from the prior year.
• Current Deferred Revenue grew to $37.6 million in Q1 2026 per JANX's latest filing, from $94000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $37.6 million in Q1 2026 and troughed at $94000.0 in Q2 2024.
• A 4-year average of $6.9 million and a median of $4.9 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue grew 12.2% in 2022, then tumbled 98.24% in 2024.
• A 4-year view of Current Deferred Revenue shows it stood at $5.4 million in 2022, then tumbled by 68.46% to $1.7 million in 2023, then tumbled by 94.49% to $94000.0 in 2024, then surged by 39890.43% to $37.6 million in 2026.
• Business Quant data shows JANX's Current Deferred Revenue at $37.6 million in Q1 2026, $94000.0 in Q2 2024, and $972000.0 in Q1 2024.